Methylfolate as Monotherapy in Depression. A Pilot Randomised Controlled Trial
Journal Title: Journal of Neurology and Psychology - Year 2015, Vol 3, Issue 1
Abstract
Background: The commonest neuropsychiatric complication of severe folate deficiency is depression. Placebo controlled trials of folates as adjunctive therapy in major depression have confirmed that they enhance the response to standard antidepressant medication, even in the absence of folate deficiency. We have undertaken a pilot randomised controlled trial of 5-methyltetrahydrofolate (5- MTHF) monotherapy against Amitriptyline in out-patients with mild to moderate depression. Methods: 31 patients, aged 20 – 69 years with DSM-111-R criteria for a depressive episode of mild to moderate severity and a Montgomery Asberg Depression Score (MADS) of at least 14 were randomly allocated to 5-MTHF 50 mgs (25 mgs biologically active) or Amitriptyline 150 mgs for 6 weeks. Clinical response was defined as a fall in MADS of 25% or more. Non-responders to initial therapy were crossed over to the alternative active therapy for a further six weeks. Haemoglobin, mean cell volume, serum and red cell folate and serum vitamin B12 were measured at entry to the study, after six weeks of initial and crossover treatment and at six months. Results: Of 19 patients randomised (n = 16) or crossed over (n = 3) to treatment with 5-MTHF for six weeks, eight (42%) responded. Of 20 patients randomised (n = 15) or crossed over (n = 5) to Amitriptyline, seven (35%) responded. Only 3 patients (10%) had low or borderline red cell folate values at randomisation. Response to 5-MTHF was associated with a significantly greater rise in red cell folate. Conclusions: Placebo controlled trials of 5-MTHF as monotherapy in depression would be justifiable. Our observations together with studies of S-adenosylmethionine (SAM) and nitrous oxide (N2O) are consistent with the hypothesis that 5-MTHF has intrinsic mood elevating properties in some patients.
Authors and Affiliations
Edward H Reynolds
Keywords
Related Articles
- EP ID EP197342
- DOI 10.13188/2332-3469.1000019
- Views 151
- Downloads 0
Biomarker Development for Brain-Based Disorders: Recent Progress in Psychiatry
Biomarkers are biological measures that are indicative of a specific disorder, its severity or response to treatment. They are widely used in many areas of medicine, but biomarker development for brain-based disorders la...
Adaptive Behavior and Family Burden in Patau Syndrome: Case Report
The Patau syndromeis a rare autosomaltrisomy, characterized by the fetal malformations involving the central nervous system, among others. The phenotype of Patau syndrome causes impact on families by the vulnerability an...
Weight Reduction Aids Antiepileptic Therapy to Restore Ovarian Functions of Epileptic Polycystic Ovary Women
Objectives: To evaluate the hormonal profile of epileptic women with polycystic ovary (PCOS) and to determine the impact of weight reduction regimen on their ovulatory function in comparison to nonepileptic PCOS women an...
Silicone Granulomas in the Setting of Acupuncture with Silicone-Coated Needles
Silicone is widely used in various capacities in medicine including aesthetic and prosthetic joint implants as well as in the coating of vials, catheters, drains, shunts, and needles [1]. Silicone-coated needles have bec...
What is the function of the Brain? What does it do and how does it do it? It functions as a Neuroregulator, which continuously regulates the Autonomic Nervous System and Physiological Systems, and enables us to Recognise that Sleep Exhibits the Characteristics of a Neurally Regulated Physiological System
The aim of this article is to provoke further discussion of the mechanisms which the brain uses to regulate the body´s function, in particular the autonomic nervous system. It focuses upon an understanding of the structu...